APA (7th ed.) Citation

C, L., AO, A., O, K., J, Z., CP, K., HC, R., . . . JP, W. (2026). Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases. Precision oncology, 1(1), . https://doi.org/10.3390/precisoncol1010005

Chicago Style (17th ed.) Citation

C, Lilieholm, et al. "Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases." Precision Oncology 1, no. 1 (2026). https://doi.org/10.3390/precisoncol1010005.

MLA (9th ed.) Citation

C, Lilieholm, et al. "Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases." Precision Oncology, vol. 1, no. 1, 2026, https://doi.org/10.3390/precisoncol1010005.